Refractory Myasthenia Gravis — A Pilot Trial of Rituxan in Refractory Myasthenia Gravis
Citation(s)
AAEM Quality Assurance Committee American Association of Electrodiagnostic Medicine. Practice parameter for repetitive nerve stimulation and single fiber EMG evaluation of adults with suspected myasthenia gravis or Lambert-Eaton myasthenic syndrome: summary statement. Muscle Nerve. 2001 Sep;24(9):1236-8.
Gajra A, Vajpayee N, Grethlein SJ Response of myasthenia gravis to rituximab in a patient with non-Hodgkin lymphoma. Am J Hematol. 2004 Oct;77(2):196-7.
Grob D Natural history of myasthenia gravis. In: Engel AG (ed). Myasthenia Gravis and Myasthenic Disorders. New York: Oxford University Press, 1999, pp 131-145.
Grollo-Lopez A, Varns C, Waldichuk C et al IDEC-C2B8 chimeric anti-CD20 antibody: Safety and clinical activity in the treatment of patients with relapsed low-grade or follicular (IWF:A-D) non-Hodgkin's lymphoma (NHL). Br J Haematol 93:283, 1996.
Oosterhuis HJ The natural course of myasthenia gravis: a long term follow up study. J Neurol Neurosurg Psychiatry. 1989 Oct;52(10):1121-7.
Osserman KE, Genkins G Studies in myasthenia gravis: review of a twenty-year experience in over 1200 patients. Mt Sinai J Med. 1971 Nov-Dec;38(6):497-537. Review.
Pascuzzi RM, Coslett HB, Johns TR Long-term corticosteroid treatment of myasthenia gravis: report of 116 patients. Ann Neurol. 1984 Mar;15(3):291-8.
Seybold ME Diagnosis of myasthenia gravis. In: Engel AG (ed). Myasthenia Gravis and Myasthenic Disorders. New York: Oxford University Press, 1999, pp 146-166.
Seybold ME Treatment of myasthenia gravis. In: Engel AG (ed). Myasthenia Gravis and Myasthenic Disorders. New York: Oxford University Press, 1999a, pp 167-201.
Zecca M, De Stefano P, Nobili B, Locatelli F Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia. Blood. 2001 Jun 15;97(12):3995-7.
Phase 1-2 Pilot Study of Rituximab (Rituxan) in Refractory Myasthenia Gravis.
Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.
Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.
Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.
Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.
Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.
